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Abstract
Background:	Patients	with	irritable	bowel	syndrome	with	diarrhea	(IBS-	D)	experience	
a range of abdominal and bowel symptoms; successful management requires allevia-
tion	of	this	constellation	of	symptoms.	Eluxadoline,	a	 locally	active	mixed	μ- and κ- 
opioid receptor agonist and δ-	opioid	receptor	antagonist,	is	approved	for	the	treatment	




adoline 75 or 100 mg or placebo. Radar plots were prepared showing pooled Weeks 
1- 26 response rates for the primary efficacy composite endpoint (simultaneous im-
provement	 in	abdominal	pain	and	stool	 consistency),	 stool	 consistency,	 abdominal	
pain,	urgency-	free	days,	and	adequate	relief,	and	change	from	baseline	to	Week	26	in	







Conclusions and Inferences: Data presentation in radar plot format facilitates inter-
pretation	across	multiple	domains,	demonstrating	that	eluxadoline	treatment	led	to	
improvements vs placebo across 13 endpoints representing the range of symptoms 
experienced	by	patients	with	IBS-	D.
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1  | INTRODUC TION
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder 
estimated	to	affect	up	to	20%	of	adults	in	the	US	population,	with	
the	diarrhea	subtype	(IBS-	D)	experienced	by	approximately	40%	of	
patients with IBS.1,2 IBS- D is characterized by recurring abdominal 
pain	associated	with	loose,	frequent	stools	in	the	absence	of	demon-
strable organic disease.3-5
While abdominal pain and diarrhea are the cardinal symptoms 
of	IBS-	D,	patients	may	experience	a	broad	range	of	abdominal	and	
bowel	 symptoms,6-8	 including	 abdominal	 bloating	 and	 distention,7 
unpredictable	 bowel	 patterns	 involving	 both	 form	 and	 frequency,	
and fecal urgency and incontinence.6,7,9 Symptoms such as bloating 
and	urgency	 are	 common	 in	 IBS-	D	and	may	be	extremely	bother-
some,	 greatly	 impacting	 patients’	 daily	 lives.	 In	 a	 survey	 including	
1001	 patients	 with	 IBS-	D,	 loss	 of	 bowel	 control	 or	 fecal	 inconti-
nence was reported as the most bothersome symptom.10 Symptoms 
of IBS- D can range from mild and intermittent to more severe and 
continuous,	with	abdominal	pain	and	bloating	being	strongly	related	
to perceived disease severity.11,12
Traditionally,	pharmacologic	management	has	primarily	involved	
addressing	specific	symptoms,	with	limited	evidence	that	many	ex-
isting treatments effectively control the multiple symptoms of IBS- 
D.13	 In	one	study,	more	than	half	of	patients	with	IBS-	D	reported	
inadequate symptom control with the currently available medi-
cation options.14 IBS- D is associated with a substantial economic 
burden in terms of its impact on work productivity and healthcare 
resource	 use,	 and	patients	with	 inadequate	 symptom	control	 use	
significantly more healthcare resources and incur significantly 
greater costs.14,15
Eluxadoline,	 a	 mixed	 μ- and κ- opioid receptor agonist and δ- 
opioid receptor antagonist approved for the treatment of IBS- D in 
adults,16	 has	demonstrated	efficacy	 for	multiple	 IBS-	D	 symptoms,	
based on 2 large Phase 3 trials. Significantly greater proportions of 
patients	receiving	eluxadoline	were	responders	vs	placebo	based	on	
a primary composite endpoint consisting of simultaneous reduction 
in abdominal pain and improvement in stool consistency.17	Further	
analyses	demonstrated	sustained	benefits	in	patients	with	IBS-	D,	as	
more than two- thirds of patients who were composite or adequate 
relief	 responders	 with	 eluxadoline	 over	 the	 first	 month	 of	 ther-
apy retained their response throughout 6 months of treatment.18 
Furthermore,	multiple	 secondary	endpoints	were	 improved	across	
both trials.
Measurement of treatment effects in IBS is inherently multi-
variate,	necessitating	presentation	 formats	 that	 can	accommodate	
multiple measures simultaneously. Radar plots are useful for visu-
ally	 presenting	 complex	multivariate	 data	 across	multiple	 domains	
or	outcomes	 in	a	 single	graph	and	 in	a	 simple,	easily	 interpretable	
manner.19,20 These graphs have been used to analyze and present 
data	 across	 a	 variety	 of	 areas	 of	medical	 research,	 from	monitor-
ing	of	chronic	liver	disease	to	brain	injury	rehabilitation,	mapping	of	
medication	 dispensing	 for	 atherosclerotic	 cardiovascular	 disease,	
and assessment of sleep disturbances.21-24
We	report	data	 from	the	2	Phase	3	studies	of	eluxadoline	and	
utilize radar plots to present the wide range of efficacy measures 
assessed	and	address	the	spectrum	of	symptoms	experienced	by	pa-
tients with IBS- D in 2 simple graphical representations.
2  | MATERIAL S AND METHODS
2.1 | Study design
Two	double-	blind,	placebo-	controlled,	Phase	3	clinical	trials	(IBS-	
3001;	 https://clinicaltrials.gov/:	 NCT01553591	 and	 IBS-	3002;	
https://clinicaltrials.gov/:	 NCT01553747)	 randomized	 patients	
1:1:1	 to	 twice-	daily	 treatment	with	eluxadoline	75	or	100	mg	or	
placebo; the methodology and results of these studies have been 
described previously.17 Both studies comprised an identical 26- 
week treatment period. IBS- 3001 was followed by a 26- week 
safety	 assessment,	 with	 a	 2-	week	 follow-	up	 period,	 while	 IBS-	
3002 was followed by a 4- week single- blind placebo withdrawal 
period.
These studies were conducted in compliance with the principles 
of	the	International	Conference	on	Harmonisation	tripartite	guide-
line	E6(R1):	Good	Clinical	Practice	and	according	to	the	Declaration	
of	Helsinki.	 The	 institutional	 review	board	 or	 ethics	 committee	 at	
each	participating	site	approved	the	protocols,	and	all	patients	pro-
vided written informed consent.
2.2 | Study assessments
Participants recorded daily and weekly assessments of IBS- D 
symptoms and bowel function using an electronic diary with an 
interactive voice response system.17	 Abdominal	 pain	 in	 the	 past	
24	hours	was	 reported	daily	 on	 an	11-	point	 scale,	where	0	 indi-
cates no pain and 10 indicates worst pain imaginable. Stool con-
sistency	was	reported	daily	on	the	Bristol	Stool	Form	Scale	(BSFS),	
a 7- point scale where 1 indicates hard stool and 7 indicates watery 
diarrhea.25	IBS-	D	global	symptom	score	(GSS)	in	the	past	24	hours	
Key Points
• Data presentation in radar plot format can facilitate 
evaluation of the diverse array of symptoms and out-
comes that are relevant to a symptom-based condition 
like irritable bowel syndrome with diarrhea (IBS-D).
•	 In	2	Phase	3	trials,	eluxadoline	treatment	improved	stool	
consistency	 and	 frequency,	 abdominal	 pain,	 bloating	
and	 discomfort,	 feelings	 of	 urgency,	 global	 symptom	
score,	and	adequate	relief.
• Radar plots provide a visual demonstration of improve-
ments	 with	 eluxadoline	 across	 13	 endpoints	 encom-
passing the diverse constellation of symptoms 
experienced	by	patients	with	IBS-D.
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was	reported	daily	on	a	5-	point	scale,	where	0	indicates	no	symp-
toms	and	4	indicates	very	severe	symptoms.	Adequate	relief	was	
assessed once weekly with a dichotomous response to the follow-
ing	question:	“Over	the	past	week,	have	you	had	adequate	relief	of	
your	IBS	symptoms?”	Abdominal	bloating	in	the	past	24	hours	was	
reported	daily	on	 an	11-	point	 scale,	where	0	 indicates	no	bloat-
ing and 10 indicates worst bloating imaginable (abdominal bloat-
ing ratings were not collected in the Spanish language version of 
the	electronic	diary).	Abdominal	discomfort	 in	 the	past	24	hours	
was	reported	daily	on	an	11-	point	scale,	where	0	indicates	no	dis-
comfort and 10 indicates worst discomfort imaginable. Number of 
bowel movements and number of urgency episodes over the past 
24 hours were recorded daily.
2.3 | Patient population
The studies enrolled patients aged 18- 80 years meeting the Rome 
III criteria for IBS- D.17,26	During	 the	week	 prior	 to	 randomization,	
eligible patients were required to report an average worst abdomi-






or gastrointestinal infection or diverticulitis in the past 3 months.
2.4 | Efficacy endpoints
As	 previously	 reported,17 the primary efficacy endpoint of both 








days,	 or	 the	 absence	 of	 a	 bowel	movement	 if	 accompanied	 by	 an	
improvement	of	≥30%	in	abdominal	pain	score.	Adequate	relief	re-
sponse	was	defined	as	a	weekly	“yes”	response	for	≥50%	of	treat-
ment weeks. Urgency- free responders were calculated using criteria 
of	≥50%	or	≥75%	of	days	with	no	diary	entry	of	urgency	episodes.	
Response	rates	were	evaluated	over	26	weeks,	requiring	a	minimum	
of 110 diary- entry days for a patient to be considered as a responder. 
Additionally,	changes	from	baseline	to	Week	26	 in	 IBS-	D	GSS,	ab-
dominal	discomfort,	abdominal	pain,	abdominal	bloating,	and	num-
ber of bowel movements were assessed.
2.5 | Data analyses
Statistical analyses for the Phase 3 trials have been described pre-
viously.17	 In	 brief,	 efficacy	 data	 from	 the	 2	 Phase	 3	 studies	were	
pooled,	with	analyses	performed	on	the	intent-	to-	treat	analysis	set.	
No	imputation	for	missing	data	was	performed,	as	diary	compliance	
rules accounted for absent diary entries. Patients with insufficient 
diary data were categorized as non- responders.
2.6 | Generation of radar plots
Response	rates	over	Weeks	1-	26	were	displayed	in	radar	plot	format,	
with the composite endpoint and adequate relief endpoint at the 12 
and	6	o’clock	positions	to	serve	as	anchors	and	the	2	components	of	
the	composite	endpoint	(stool	consistency	and	pain	[≥30%	improve-





no P- values are presented for this multiple endpoint presentation.
3  | RESULTS
3.1 | Baseline demographics and disease 
characteristics
Across	both	studies,	2428	patients	were	enrolled	(1282	in	IBS-	3001;	
1146 in IBS- 3002). Patient demographics and baseline character-
istics were balanced between the 2 individual studies and across 
treatment groups.17	Mean	age	(SD)	was	44.9	(13.7)	in	IBS-	3001	and	
45.9	(13.5)	in	IBS-	3002,	with	a	greater	proportion	of	female	patients	
in both studies (IBS- 3001: 65.4%; IBS- 3002: 67.0%). In the pooled 
Phase	3	population,	baseline	disease	characteristics	were	similar	be-
tween treatment groups (Table 1).
3.2 | Proportions of responders over Weeks 1- 26 




(Figure	1).	 Composite	 responder	 proportions	 have	 been	 described	
previously and were 26.7% (216/808) and 31.0% (250/806) with 
eluxadoline	75	and	100	mg,	 respectively,	 vs	19.5%	 (158/809)	with	
placebo (P	<	.001	vs	placebo	for	both	comparisons).17
Proportions	of	responders	to	eluxadoline	were	greater	than	placebo	
for symptom components of the composite endpoint: 31.1% (251/808) 
and	36.8%	 (297/806)	of	 patients	were	 stool	 consistency	 responders	
with	eluxadoline	75	and	100	mg,	respectively,	vs	23.9%	(193/809)	with	
placebo,	 and	 46.3%	 (374/808)	 and	 48.3%	 (389/806)	 were	 abdomi-
nal	pain	responders	with	eluxadoline	75	and	100	mg,	respectively,	vs	
44.0%	(356/809)	with	placebo	using	the	criteria	of	≥30%	improvement	
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Urgency- free days responder proportions were greater with 
eluxadoline	 vs	 placebo	 for	 both	 the	 ≥75%	 urgency-	free	 days	 and	
the	 ≥50%	 urgency-	free	 days	 response	 criteria:	 26.5%	 (214/808)	
and	27.8%	(224/806)	of	patients	were	≥75%	urgency-	free	days	re-




3.3 | Change from baseline to Week 26 in the 
pooled Phase 3 trial population
Patients	treated	with	eluxadoline	displayed	larger	changes	from	baseline	
to	Week	26	vs	placebo	across	all	efficacy	measures	assessed,	with	ob-




Eluxadoline	 treatment	 improved	 abdominal	 discomfort,	 pain,	
and bloating vs placebo: weekly mean abdominal discomfort 
scores decreased from baseline to Week 26 by 3.3 and 3.4 points 
with	 eluxadoline	 75	mg	 (n	=	515)	 and	 100	mg	 (n	=	528),	 respec-
tively,	vs	2.8	points	with	placebo	(n	=	526);	weekly	mean	abdom-
inal	pain	scores	decreased	by	3.3	and	3.4	points	with	eluxadoline	
75	mg	 (n	=	515)	and	100	mg	 (n	=	528),	 respectively,	vs	3.0	points	
with	 placebo	 (n	=	526),	 and	 weekly	 mean	 abdominal	 bloating	
scores	 decreased	 by	 2.6	 and	 2.8	 points	 with	 eluxadoline	 75	mg	
(n	=	416)	 and	 100	mg	 (n	=	438),	 respectively,	 vs	 2.3	 points	 with	
placebo	(n	=	419).
Patients	 receiving	 eluxadoline	 also	 reported	 improved	 bowel	
movement	 frequency,	 with	 a	 daily	mean	 number	 of	 bowel	move-
ments	 decrease	 of	 2.0	 for	 both	 eluxadoline	 75	mg	 (n	=	515)	 and	
100	mg	(n	=	528)	vs	a	decrease	of	1.6	with	placebo	(n	=	526).
4  | DISCUSSION
Presentation of pooled efficacy data from 2 large Phase 3 stud-
ies	in	radar	plots	demonstrates	that	eluxadoline	treatment	offers	
benefits across a broad range of abdominal and bowel symptoms 
experienced	 by	 patients	 with	 IBS-	D,	 including	 abdominal	 pain,	
bloating,	diarrhea	(stool	consistency	and	frequency),	and	fecal	ur-
gency. Two global measures commonly used to assess treatment 
efficacy	 in	 IBS-	D,	 adequate	 relief	 and	GSS,	were	 also	 improved,	
Placebo (n = 809)
Eluxadoline  
75 mg (n = 808)
Eluxadoline 
100 mg (n = 806)
Weekly	stool	consistency,	
mean (SD)
6.24 (0.41) 6.25 (0.40) 6.25 (0.42)
Weekly	abdominal	pain,	
mean (SD)
6.14 (1.53) 6.07 (1.53) 6.07 (1.51)
Weekly	IBS-	D	GSS,	
mean (SD)
2.85 (0.55) 2.78 (0.54) 2.83 (0.53)
Weekly	abdominal	bloating,	
mean (SD)a
5.90	(2.08) 5.81 (2.02) 5.73 (2.07)
Weekly abdominal 
discomfort,	mean	(SD)
6.33 (1.50) 6.28 (1.53) 6.22 (1.51)
Daily number of bowel 
movements,	mean	(SD)
4.85 (2.52) 4.78 (2.53) 4.95	(3.60)
Daily number of urgency 
episodes,	mean	(SD)





cates no symptoms and 4 indicates very severe symptoms; abdominal bloating score was reported 
on	an	11-	point	scale,	where	0	indicates	no	bloating	and	10	indicates	worst	bloating	imaginable;	ab-
dominal	discomfort	score	was	reported	on	an	11-	point	scale,	where	0	indicates	no	discomfort	and	10	
indicates worst discomfort imaginable. Patients were asked to record the number of bowel move-
ments and urgency episodes daily over the past 24 h.
aPatients who responded to the interactive voice response system items in Spanish were not pre-
sented	with	 the	bloating	 item:	placebo,	n	=	670;	eluxadoline	75	mg,	n	=	687;	eluxadoline	100	mg,	
n	=	691.
TABLE  1 Baseline symptom scores: 
pooled Phase 3 population
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further	 illustrating	 the	 broad-	ranging	 effects	 of	 eluxadoline.	
These improvements are evidenced by the separation observed 
between	the	data	points	for	eluxadoline	vs	placebo	on	each	axis	
of the radar plots presented; although the magnitude of improve-





of stool consistency responders and abdominal pain responders 
(using	a	criteria	of	≥30%	 improvement	 from	baseline)	were	 similar	
in the individual Phase 3 trials17 and in the pooled population over 
Weeks	 1-	26,	 and	 proportions	 of	 adequate	 relief	 responders	 over	
Weeks 1- 12 in the individual studies17 were similar to those seen 
across Weeks 1- 26 in the present analyses. Proportions of abdominal 
pain	responders	using	criteria	of	≥40%	and	≥50%	improvement	from	




pooled Phase 3 population.
Effective	management	 strategies	 for	 IBS-	D,	particularly	 in	pa-
tients	with	moderate	 or	more	 severe	 disease,	 require	 treatments	
that address not only the primary symptoms but also the range 
of	 symptoms	 experienced,	 including	 pain,	 bloating,	 and	 urgency,	
which	may	be	particularly	bothersome	for	patients.	Existing	treat-
ments have been shown to be beneficial for specific symptoms or 
groups	of	 symptoms	 for	 IBS-	D,	 such	as	antidiarrheals	 for	normal-
izing stool consistency and antispasmodics for relief of abdominal 
pain;	however,	the	evidence	supporting	the	efficacy	of	many	phar-
macological therapies in providing global relief of IBS- D symptoms 
is variable.8,13,29,30	The	data	presented	in	this	study,	therefore,	sug-
gest	that	eluxadoline	provides	a	valuable	new	option	for	the	man-
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This	analysis	should,	however,	be	interpreted	in	the	light	of	certain	
limitations,	as	the	data	for	the	range	of	endpoints	presented	were	not	
normalized and so do not permit quantitative comparison of the mag-
nitude	of	changes	observed	with	eluxadoline	between	different	effi-
cacy	measures.	Radar	plots	in	this	instance	are,	therefore,	best	suited	







The use of radar plots to display efficacy data from 2 large Phase 
3 studies facilitates simultaneous interpretation of data across mul-
tiple	domains,	supporting	previous	findings	and	demonstrating	that	
treatment	with	eluxadoline	led	to	consistent	improvements	vs	pla-
cebo across 13 endpoints representing the range of abdominal and 
bowel	 symptoms	experienced	by	patients	with	 IBS-	D.	The	 robust-
ness	and	consistency	of	these	data	suggest	that	eluxadoline	treat-
ment provides effective global relief of IBS- D symptoms.
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